contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


oncozenge-ab-nomination-committee-appointed

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

OncoZenge is a Swedish pharmaceutical company that develops treatments for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. The company's product candidate is undergoing further development after completing phase 2 studies to form the basis for application for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.

OncoZenge

STOCKHOLM, October 9, 2025. In accordance with the resolution of the Annual General Meeting on May 28, 2025, the Chairman of the Board has contacted the company's three largest shareholders ...

<div class="mfn-preamble"><p><strong>STOCKHOLM, October 9, 2025. In accordance with the resolution of the Annual General Meeting on May 28, 2025, the Chairman of the Board has contacted the company's three largest shareholders or owner groups in terms of votes, each of whom was offered to appoint a representative to constitute the company's Nomination Committee for the Annual General Meeting for the financial year January - December 2025. All three largest shareholders or owner groups have accepted to form the Nomination Committee together with the Chairman of the Company's Board of Directors.</strong></p></div><div class="mfn-body"><p><strong>OncoZenge's Nomination Committee for the Annual General Meeting for the financial year January - December 2025 consists of:</strong></p><ul><li>Niclas Holmgren</li><li>Karl Tobieson, appointed by Linc AB</li><li>Andreas Özbek</li><li>Daniel Ehrenstråhle, Chairman of the Board</li></ul><p>The Nomination Committee together represents 28.5 percent of the voting rights of all voting shares in the company as of September 30, 2025.</p><p>The Nomination Committee's task is to present proposals to the Annual General Meeting for the financial year January - December 2025 regarding the election of the Chairman of the Board and other members of the Board, Board fees and other remuneration to the Board members, as well as election and remuneration of auditors.</p><p>The Annual General Meeting for the financial year January - December 2025 will be held on May 27, 2026. Shareholders who wish to submit proposals to OncoZenge's Nomination Committee can do so by e-mail to info@oncozenge.se no later than April 10, 2026.</p></div><div class="mfn-footer mfn-c36bd55b4ec2"><p><strong class="mfn-heading-1">BupiZenge™ - Potential to be the leading treatment for oral pain.</strong><br> </p></div><div class="mfn-footer mfn-e1b84a9622e9"><p><strong class="mfn-heading-1">Contacts</strong><br>Daniel Ehrenstråhle&nbsp;Chairman of the Board E-mail: daniel.ehrenstrahle@oncozenge.se<br>Stian Kildal CEO Mobile: +46 76 115 3797 E-mail: stian.kildal@oncozenge.se</p></div><div class="mfn-footer mfn-ba6514542f1c"><p><strong class="mfn-heading-1">About</strong><br>OncoZenge AB (publ) is a clinical-stage pharmaceutical company developing an innovative, effective, and well-tolerated treatment for oral pain in conditions where current options are insufficient, such as oral mucositis from cancer therapy. Its lead candidate, BupiZenge™, represents a novel formulation of bupivacaine in a lozenge form, aimed at providing rapid and sustained local pain relief without the risks associated with systemic opioids. OncoZenge is headquartered in Stockholm, Sweden, and is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ. For more information, please visit <strong><a rel="noopener" href="http://www.oncozenge.se/">www.oncozenge.se</a></strong>.</p><p><strong>OncoZenge AB</strong><br>Gustavslundsvägen 34, 167 51 Stockholm, Sweden</p><p><strong>Certified Adviser</strong><br>OncoZenge's Certified Adviser is Redeye AB.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/fd7d282d-52f7-4951-8943-e42e67ee1fe0/oncozenge-ab-nomination-committee-appointed.pdf" class="mfn-generated mfn-primary">OncoZenge AB Nomination Committee Appointed</a></p></div>